Drug intelligence / Profile preview

MNI-513

Development stage: Phase 1
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

MNI-513 is a small molecule radiotracer developed for use in positron emission tomography (PET) imaging. Its primary application is the detection and exclusion of cerebral amyloid beta plaques in the brain, which are characteristic of Alzheimer's disease. The compound is designed to bind specifically to amyloid beta aggregates, allowing visualization and quantification through PET imaging. This makes it a valuable tool for both clinical research and potential diagnostic purposes in neurodegenerative diseases such as Alzheimer's disease[2][3][1].

Targets

Amyloid fibrilsAmyloid-beta aggregate (N-terminal epitope)

Beyond the preview

Go deeper on MNI-513.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MNI-513.